BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 4, 2018
View Archived Issues
FDA grants orphan drug designation to BN-Brachyury as treatment for chordoma
Read More
Refuge Biotechnologies completes series B financing
Read More
Azitra raises new financing to advance pipeline
Read More
Coherus BioSciences announces re-submission of BLA for CHS-1701
Read More
Daiichi Sankyo profiles highlights of fourth quarter of fiscal 2017
Read More
Abbisko presents novel candidates with promising preclinical profiles
Read More
Phase I results reported for analgesic CCR2 antagonist CNTX-6970
Read More
RBH-61, a dual SEH/PDE inhibitor for inflammatory pain
Read More
FDA grants two fast track designations for 5F9
Read More
Ocular Therapeutix doses first patient in phase I clinical trial of OTX-TIC
Read More
Bristol-Myers Squibb presents new apelin receptor agonists
Read More
Ferring Pharmaceuticals acquires option to commercialize nadofaragene firadenovec/Syn3
Read More
AbbVie divulges novel BRD4 inhibitors
Read More
Jiangsu Hengrui Medicine and collaborator disclose TGFR-1 inhibitors
Read More
Sanofi reviews key events of first quarter 2018
Read More
Phase III trial of ranibizumab biosimilar FYB-201 meets primary endpoint
Read More
RTI International discovers new APLNR agonists
Read More
Dong-A Socio Holdings identifies Mer inhibitors
Read More
Phase I trial begins of CS-1002 for advanced solid tumors begins in Australia
Read More
FDA joint advisory committee meeting recommends against stannsoporfin
Read More
Moderna Therapeutics and Merck & Co. expand cancer collaboration
Read More
New albumin-binding compounds from CytRx show antitumor activity in xenograft models
Read More
FDA approves AndexXa to reverse factor Xa inhibitors
Read More
Altum Pharmaceuticals acquires Lexi Pharma
Read More
First patient dosed in phase II study of AG-10 in ATTR cardiomyopathy
Read More
DLK inhibitor shows promising data in vivo
Read More
Casma Therapeutics launched to develop breakthrough therapies by boosting autophagy
Read More
OTL-200 receives rare pediatric disease designation from the FDA
Read More
EMA validates type II variation application for Opdivo plus Yervoy in first-line NSCLC
Read More
Sarepta partners with Myonexus to advance gene therapies for limb-girdle muscular dystrophy
Read More